MALVERN, Pa., June 06, 2025 - TELA Bio, Inc. (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, announced the approval of a new inducement grant for Jim Hagen, the company's Senior Vice President of Strategic Commercial Operations. Effective June 2, 2025, Hagen will receive an option to purchase 75,000 shares of TELA Bio's common stock, along with restricted stock units covering 30,000 shares. The stock options are priced at $1.42 per share, the closing price on the grant date, with a ten-year term. They will vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments over the following 36 months. The restricted stock units will also vest in equal annual installments over four years. These awards are contingent upon Hagen's continued service with TELA Bio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.